Pharmaceuticals, Biotechnology and Life Sciences
Vertex’s third medicine approved to treat the underlying cause of CF in eligible patients in this age range-
– First-quarter 2019 product revenues of $857 million, a 34% increase compared to $638 million in 2018- – First-quarter 2019…
BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Charles (Charlie) Wagner as Executive Vice President and Chief…
Vertex Pharmaceuticals Limitedgot will extend label for its cystic fibrosis children patients treatment Orkambi in Europe, after the Union’s Commissions’ approval.
Vertex Pharmaceuticals has appointed new medical boss and Executive Vice President of global medicines business, which will be effective in…
Vertex Pharmaceuticals wants to submit a New Drug Application in the USA, so it will soon give the final test…
Vertex Pharmaceuticals Incorporated can now offer Symdeko for treating the underlying cause of cystic fibrosis (CF) for more certain patients.…
Vertex Pharmaceuticals will move its cystic fibrosis treatment VX-659 and VX-445 into Phase 3, the company said Wednesday, after the initial…
Vertex Pharmaceuticals got European Commission’s grant to extend the Marketing Authorization for ORKAMBI, the first medicine to treat the basic…
Vertex Pharmaceuticals Incorporated on Wednesday announced the appointment of Tom Graney as the Senior Vice President and Chief Financial Officer (CFO).